Law360, New York (July 30, 2010, 4:59 PM ET) -- Unmoved by calls from the generic-drug industry to revisit the decision, a federal appeals court has refused to reconsider en banc an April ruling for Novo Nordisk A/S in its patent fight with Caraco Pharmaceutical Laboratories Ltd. over the diabetes drug Prandin.
The U.S. Court of Appeals for the Federal Circuit said Thursday that it would not reconsider its April 14 split ruling for Novo Nordisk, a finding the generics industry says will hamper the U.S. Food and Drug Administration's ability to process generic drug applications....
Fed. Circ. Won't Rehear Prandin Use Code Patent Case
To view the full article, take a free trial now.
